This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    PSA Doubling Time (PSADT) Calculator

    Calculates rate of PSA doubling in prostate cancer (correlates with survival).
    Favorite

    INSTRUCTIONS

    Use in patients with prostate cancer. Do not use for screening or diagnosis.

    When to Use
    Pearls/Pitfalls
    Why Use

    • Patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA ≥0.2 ng/mL if radical prostatectomy or confirmed PSA rise of ≥2 ng/mL above the nadir PSA level if radiation therapy.

    • PSADT has limited value in prostate cancer screening or diagnosis.

    • For patients with biochemical recurrence of prostate cancer, optimal PSADT calculation should include all PSA values of the individual within two years of initially documented PSA recurrence.

    • Entering more values improves accuracy of estimation.

    • Shorter PSADT reflects faster increase in PSA levels, while longer PSADT reflects a slower increase in PSA levels over time.

    • In patients with biochemical recurrence, PSADT:

      • Predicts risk of metastasis and risk of dying of prostate cancer when combined with other factors such as the Gleason Score and length of time to biochemical recurrence.

      • Helps identify patients more likely to develop clinically significant disease.

      • Helps guide patient selection for salvage local therapy or androgen deprivation therapy.

      • Helps guide utilization and timing of imaging studies.

    • For patients with M0 castration resistant disease, PSADT helps guide patient selection for observation, second generation antiandrogen, androgen metabolism inhibitor, or other secondary hormone treatments.

    • Used in assessment of eligibility for clinical trials.

    ng/mL
    ng/mL
    months
    No
    Yes

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    Content Contributors
    • Nazli Dizman, MD
    About the Creator
    Dr. Charles R. Pound
    Are you Dr. Charles R. Pound?
    Content Contributors
    • Nazli Dizman, MD